Literature DB >> 29221733

Diagnostic performance of commercial serological assays measuring Bordetella pertussis IgG antibodies.

Giorgio Fedele1, Pasqualina Leone2, Stefania Bellino2, Ilaria Schiavoni2, Claudia Pavia3, Tiziana Lazzarotto4, Paola Stefanelli5.   

Abstract

Due to their specificity to B. pertussis antigens, immunoglobulin G (IgG) antibodies should be measured primarily for diagnosing pertussis. We compared the diagnostic performance of commercially available enzyme-linked immunosorbent assays (ELISAs) and chemiluminescent immunoassays (CLIAs) measuring IgG to B. pertussis antigens. An in-house ELISA with purified pertussis toxin (PT) was used as reference system. Commercial assays using PT only as coating antigen showed better performance as compared to those using a mixture of different antigens. The best diagnostic performances were achieved by CLIAs. Results were analyzed using a dual cutoff of either ≥125IU/mL anti-PT IgG or ≥62IU/mL anti-PT IgG for the in-house ELISA and accordingly to package inserts for commercial assays. Using the in-house ELISA at a 62 IU/mL cutoff, as the gold standard for interpretation of results from the commercial kits, resulted in lower sensitivity and higher specificity as compared to 125IU/mL, thus, it may be especially useful in outbreak situations when high specificity is required.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B. pertussis; Diagnosis; IgG; Serology

Mesh:

Substances:

Year:  2017        PMID: 29221733     DOI: 10.1016/j.diagmicrobio.2017.11.006

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  1 in total

1.  Pertussis over two decades: seroepidemiological study in a large population of the Siena Province, Tuscany Region, Central Italy.

Authors:  Geraldo Tadinho Monteverde Spencer; Angela Azzarello; Serena Marchi; Emanuele Montomoli; Edmond J Remarque; Simonetta Viviani; Claudia Maria Trombetta
Journal:  BMJ Open       Date:  2019-10-30       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.